Grant: Collaborative Research and Development Grants
Université de Montréal
$30,000.00
Biomarkers discovery program for chronic obstructive pulmonary diseases (COPD)
EF 2009-10
Résumé
Chronic Obstructive Pulmonary Disease (COPD) regroups disorders such as emphysema and chronic bronchitis, and its incidence as leading cause of death among Canadians, is taking alarming proportion. This disease is characterized by impaired lung function, inflammation and scarring of bronchial tubes, and degradation of elastin-containing tissues. To date, only a few COPD biomarkers are currently used despite their increasing needs as diagnostic and prognostic indicators of disease progression. The objectives of this project are to develop new and highly sensitive methods enabling the quantitation of known elastin degradation products in urine and the identification of novel biomarkers correlated with COPD. Nano-scale liquid chromatography interfaced to either a Q-Trap or a high performance Orbitrap mass spectrometer will be used to obtain comprehensive ion profiles and targeted identification of urinary metabolites from a representative set of healthy and COPD patient samples. Comprehensive data mining and clustering analyses will be performed using in-house programs to profile the abundance of molecular species across sample types and replicates. More importantly, the methods developed as part of this project will be of practical use to Merck Frosst Canada, our industrial collaborator, to monitor treatment efficacy following drug administration.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
354854-2007
Name nom
Thibault, Pierre
Department département
Chimie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2007
Award amount
30000
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
2
Nb partie
2
Application title
Biomarkers discovery program for chronic obstructive pulmonary diseases (COPD)
Keyword
NA
Application summary
Chronic Obstructive Pulmonary Disease (COPD) regroups disorders such as emphysema and chronic bronchitis, and its incidence as leading cause of death among Canadians, is taking alarming proportion. This disease is characterized by impaired lung function, inflammation and scarring of bronchial tubes, and degradation of elastin-containing tissues. To date, only a few COPD biomarkers are currently used despite their increasing needs as diagnostic and prognostic indicators of disease progression. The objectives of this project are to develop new and highly sensitive methods enabling the quantitation of known elastin degradation products in urine and the identification of novel biomarkers correlated with COPD. Nano-scale liquid chromatography interfaced to either a Q-Trap or a high performance Orbitrap mass spectrometer will be used to obtain comprehensive ion profiles and targeted identification of urinary metabolites from a representative set of healthy and COPD patient samples. Comprehensive data mining and clustering analyses will be performed using in-house programs to profile the abundance of molecular species across sample types and replicates. More importantly, the methods developed as part of this project will be of practical use to Merck Frosst Canada, our industrial collaborator, to monitor treatment efficacy following drug administration.